Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03927703 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Efficacy & Safety of SB206 & Vehicle Gel for the Treatment of MC
A Phase 3 study, sponsored by Novan.
- Completed
- Registry status
- Phase 3
- Development phase
- 355
- Enrollment target
NCT03927703 is a Phase 3 study that has completed, run by Novan. The registered enrollment target is 355 participants.
The verdict
NCT03927703, a Phase 3 study, has completed, sponsored by Novan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 355 participants
- Enrollment target
Study Summary
This is a Phase 3 multi-center, randomized, double-blind, vehicle-controlled, parallel group study to be conducted in up to approximately 340 subjects ≥6 months of age with MC. Subjects or their caregivers will apply SB206 12% or Vehicle Gel once daily for a minimum of 4 weeks and up to 12 weeks to all lesions identified at Baseline and new treatable lesions that arise during the course of the study.
Interventions
- DRUG Placebo
- DRUG SB206 12%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 355 participants |
| Start Date | 2019-06-13 |
| Est. Completion | 2020-02-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03927703
The ClinicalTrials.gov registry entry for NCT03927703 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 355 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novan, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03927703 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03927703 about?
NCT03927703 is a clinical study titled "A Phase 3 Efficacy & Safety of SB206 & Vehicle Gel for the Treatment of MC". This is a Phase 3 multi-center, randomized, double-blind, vehicle-controlled, parallel group study to be conducted in up to approximately 340 subjects ≥6 months of age with MC. Subjects or their caregivers will apply SB206 12% or Vehicle Gel once daily for a minimum of 4 weeks and up to 12 weeks to ...
What is the current status of trial NCT03927703?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 355 participants. The study started on 2019-06-13. Estimated completion is 2020-02-03.
What interventions are being tested in trial NCT03927703?
The interventions under investigation include: Placebo (DRUG), SB206 12% (DRUG).
Who is sponsoring clinical trial NCT03927703?
This trial is sponsored by Novan, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.